Boehringer and Lilly's Synjardy gains EU approval

28 May 2015

German family-owned pharma major Boehringer Ingelheim and partner US peer Eli Lilly’s (NYSE: LLY) Synjardy (empagliflozin/metformin)has been granted marketing authorization by the European Commission for the treatment of adults with type 2 diabetes (T2D) in the European Union.

Empagliflozin alone was approved in the EU in May 2014 and is available in many countries as an oral, once-daily tablet, marketed as Jardiance. The new fixed-dose combination of empagliflozin and metformin is still under review in the USA, where earlier this year the Food and Drug Administration approved Glyxambi (empagliflozin/linagliptin) to improve glycemic control in adults with type 2 diabetes (The Pharma Letter February 22).

Approved indications

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK